Healthcare Global Enterprises Ltd (HCG)
🎯 Key Takeaways
- Healthcare Global Enterprises Ltd (HCG) is in a strategic expansion phase within the oncology and cancer care segment, leveraging its core expertise to scale infrastructure and capture a growing $535 billion market by 2030. The company has demonstrated financial recovery with sequential revenue growth and improved EBITDA margins, supported by targeted investments in new facilities and acquisitions.
- Revenue grew 6.6% QoQ to ₹695 in Q1FY27.
- ⚠️ High capital intensity from expansion into new geographies and facilities may pressure cash flows if revenue growth slows.
- Market Cap
- ₹10,337
- P/E Ratio
- 310.5
- P/B Ratio
- 7.76
- ROE
- 1.7%
- ROCE
- 9.4%
- Debt/Equity
- 0.68
- Promoter
- 64.2%
📖 The Story
Healthcare Global Enterprises Ltd (HCG) is in a strategic expansion phase within the oncology and cancer care segment, leveraging its core expertise to scale infrastructure and capture a growing $535 billion market by 2030. The company has demonstrated financial recovery with sequential revenue growth and improved EBITDA margins, supported by targeted investments in new facilities and acquisitions. Management is focused on operational scaling and capital efficiency to drive sustainable profitability.
📰 What's Happening
The 28th Annual General Meeting on August 27, 2026, approved key governance items including the reappointment of directors Simrun Mehta and Akshay Tanna, ratification of cost auditor remuneration, and extension of Anjali Ajaikumar’s consultancy agreement. The meeting also endorsed the adoption of FY 2025-26 audited financial statements. Management highlighted expansion plans to 25 hospitals across 19 Indian cities and Kenya, with rights issue proceeds allocated to acquisitions and debt reduction. New cancer care facilities were launched in Hebbal and Vizag, and the company emphasized precision oncology and digital health as strategic pillars. Shareholder approvals were sought for capital actions tied to the rights issue, which increased equity proportion to 95%.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 647 | 633 | 652 | 695 |
| Operating Profit | 61 | 49 | 62 | 52 |
| OPM % | 9.3% | 7.7% | 9.6% | 7.5% |
| Net Profit | 21 | -8 | 4 | 16 |
| EPS | ₹1.16 | ₹-0.68 | ₹0.15 | ₹0.92 |
Revenue has shown consistent growth over the past four quarters, rising from ₹633 million in December 2025 to ₹695 million in June 2026, indicating operational momentum. Operating margins have stabilized around 7.5–9.6%, with the latest quarter achieving ₹52 million in operating profit on ₹695 million revenue. Net profit turned positive in June 2026 at ₹16 million after a loss in December 2025, supported by improved cost control and scale. EBITDA margin improved to 18.30% as per AGM commentary, reflecting benefits from expansion initiatives and efficient resource allocation.
🔮 Management Outlook & What's Next
Management has outlined a clear expansion strategy, targeting 25 hospitals across 19 Indian cities and Kenya, with a focus on precision oncology and digital health. The rights issue proceeds are explicitly allocated to acquisitions and debt reduction, signaling a dual emphasis on growth and balance sheet optimization. While no formal financial targets were provided beyond the expansion timeline, management underscores the $535 billion market opportunity in India’s cancer care sector by 2030 as a key driver for strategic investments.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 139 | 139 | 149 | 141 |
| Reserves | 783 | 722 | 1,183 | 780 |
| Borrowings | 1,837 | 1,558 | 910 | 1,768 |
| Total Liabilities | 3,543 | 3,067 | 3,923 | 3,586 |
| Fixed Assets | 1,963 | 1,839 | 2,462 | 1,956 |
| Investments | 11 | 11 | 14 | 13 |
| Total Assets | 3,543 | 3,067 | 3,923 | 3,586 |
The balance sheet shows a steady increase in total assets from ₹3,543 million in March 2025 to ₹3,923 million in March 2026, driven by investments in infrastructure and acquisitions. Borrowings rose to ₹1,735 million from ₹1,002 million over the same period, indicating active capital deployment, likely for expansion. Equity and reserves have grown modestly, from ₹920 million to ₹1,334 million, suggesting capital base expansion. The rising debt levels are being managed alongside profitability improvements, with proceeds from rights issue likely funding part of the leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | +317 | +347 |
| Investing | -488 | -177 |
| Financing | -42 | +241 |
| Net Cash Flow | -213 | +410 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 63.8% | 63.8% | 64.2% | 64.2% |
| FII | 3.6% | 3.2% | 2.8% | 2.7% |
| DII | 18.4% | 18.3% | 18.9% | 19.2% |
| Public | 10.4% | 11.2% | 10.8% | 10.8% |
| # Shareholders | 46,970 | 45,366 | 47,649 | 48,905 |
Promoter holding has remained stable at 64.21% over the last four quarters, indicating confidence in long-term strategy. FII ownership has slightly increased from 2.74% to 2.75%, while DII rose from 18.3% to 19.2%, suggesting growing institutional interest. The number of shareholders has increased from 45,366 to 48,905, reflecting broader retail participation. No significant selling or pledging signals are evident, and the stable promoter stake supports continuity in strategic execution.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 61.0 | 22.1% | — | 0.60 |
| MAXHEALTH | 97,412 | 66.8 | 14.4% | — | 0.27 |
| MANIPALHOS | 94,970 | — | — | — | 1.25 |
| ASTERDM | 65,184 | 121.0 | 12.9% | — | 0.17 |
| FORTIS | 62,782 | 59.9 | 13.3% | — | 0.29 |
| MEDANTA | 38,551 | 69.3 | 21.9% | — | 0.10 |
| NH | 37,160 | 45.3 | 13.7% | — | 1.07 |
| LALPATHLAB | 32,549 | 46.8 | 29.6% | — | 0.00 |
| KIMS | 32,181 | 150.2 | 9.7% | — | 1.44 |
| POLYMED | 16,587 | 52.6 | 15.1% | — | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. High capital intensity from expansion into new geographies and facilities may pressure cash flows if revenue growth slows. 2. Rising borrowings to fund acquisitions and expansion increase financial leverage, which could affect resilience during economic downturns. 3. Dependence on the oncology segment exposes the company to regulatory, clinical, and market-specific risks in a competitive and evolving healthcare landscape. 4. Limited export revenue contribution (2.13%) suggests geographic diversification remains nascent, constraining revenue mix optimization.
📋 Recent Filings
- 🟡 voting results2026-09-18HealthCare Global Enterprises Limited held its 28th Annual General Meeting on September 18, 2026, via video conferencing, approving all listed resolut…
- 🟡 Board Meeting2026-09-18HealthCare Global Enterprises held its 28th AGM on September 18, 2026, via video conferencing, with 110 shareholders participating. The meeting approv…
- 🔴 Announcement2026-09-17HealthCare Global Enterprises announced an investor meeting on September 22, 2026, in Mumbai with Prabhudas Lilladher, covering one-on-one and group d…
- 🔴 Announcement2026-09-16HealthCare Global Enterprises Limited announced its schedule for an analyst and institutional investor meeting on September 21, 2026, in Mumbai, featu…
- 🟡 Board Meeting2026-09-09HealthCare Global Enterprises Limited announced on September 9, 2026, that its Nomination and Remuneration Committee approved the grant of 64,46,843 e…
- 🔴 annual report2026-08-28HealthCare Global Enterprises Limited announced that its 28th Annual General Meeting will be held on September 18, 2026, via video conference, with re…
- 🔴 annual report2026-08-27The filing is a notice of the 28th Annual General Meeting (AGM) of HealthCare Global Enterprises Limited (HCG) scheduled for September 18, 2026, condu…
- 🟡 sustainability report2026-08-27HealthCare Global Enterprises Limited (HCG) filed its 5th Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 on August 2, 2026, d…
- 🟡 Board Meeting2026-08-27The 28th Annual General Meeting of Healthcare Global Enterprises Ltd (HCG) was held on August 27, 2026, for FY 2025-26. Key resolutions included appro…
- Announcement2026-08-10Healthcare Global Enterprises reported Q1 FY27 revenue of INR6,951 million, up 13% YoY, with adjusted EBITDA rising 20% to INR1,339 million and EBITDA…
🧠 Analyst's Read
HCG is executing a clear growth strategy in oncology with improving operational trends and institutional investor interest, but the pace of expansion and rising leverage require disciplined execution. The next key watchpoints are the successful integration of new facilities and acquisitions, and whether margins can be sustained amid scaling. Investors should monitor progress on debt reduction and the contribution of new hospitals to top-line growth in upcoming quarters.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when HCG files new disclosures
Track HCG filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track HCG — FreeFree account · 2 AI queries/day